The GLP-1 Compounding Landscape in 2026
GLP-1 receptor agonists — including semaglutide and tirzepatide — emerged as breakthrough therapies for type 2 diabetes and obesity management, with Phase 3 trials demonstrating 14.9–20.9% body weight reduction over one year. Surging demand created declared FDA drug shortages beginning in 2022, enabling compounding pharmacies to legally supply formulations under the FD&C Act.
The FDA declared both shortages resolved — tirzepatide in late 2024, semaglutide in February 2025. Enforcement deadlines followed: 503A pharmacies by April 2025, 503B outsourcing facilities by May 22, 2025. Limited compounding pathways remain available under 503A for patient-specific clinical needs not met by commercially available products.
Practitioner note: This page is an educational resource. ExaVeyra Sciences does not make clinical efficacy claims. All supply is intended for licensed practitioners operating within applicable federal and state regulatory frameworks. Sourcing decisions should be guided by current FDA guidance and legal counsel.
503A vs. 503B: Side-by-Side
| 503A — State-Licensed Pharmacy | 503B — FDA Outsourcing Facility | |
|---|---|---|
| Regulatory basis | Section 503A of FD&C Act | Section 503B of FD&C Act |
| Batch production | Individual prescriptions only | Large-scale batches permitted |
| FDA oversight | State pharmacy boards primary | Direct FDA registration + inspection |
| GMP requirements | State standards apply | Federal cGMP standards required |
| Batch testing | Variable by state | Required: sterility, potency, impurities |
| Current GLP-1 status | Limited — patient-specific need only | Ceased (post-shortage resolution) |
| Distribution scope | To specific patient per Rx | To practitioners & healthcare facilities |
The ExaVeyra Supply Standard
Verified Source Integrity
ExaVeyra sources exclusively from FDA-registered 503B facilities with documented batch testing, sterility certificates, and current cGMP compliance records available upon request.
NPI-Verified Access
Wholesale pricing is gated behind NPI verification. All practitioner accounts are reviewed against the NPPES registry before wholesale access is granted.
Regulatory Navigation
With the FDA enforcement landscape evolving rapidly, ExaVeyra publishes ongoing compliance updates for practitioners navigating the post-shortage 503A/503B framework.
Cold-Chain Logistics
Temperature-controlled shipping with documented chain of custody. All GLP-1 formulations are shipped with validated cold-chain packaging maintaining 2–8°C integrity.
Common Questions
The research citations and scientific content on this page are provided for educational and informational purposes only. This content does not constitute medical advice, diagnosis, or treatment recommendations. ExaVeyra Sciences does not make clinical efficacy claims for any products. All cited publications are independently authored peer-reviewed studies available through PubMed, PMC, or DOI. Practitioners should consult current FDA guidance and applicable regulations before clinical use.